Disease relevance of KIAA1212

• Analysis using clinical stool specimens revealed that the present system was capable of detecting SaV GI, GII, GIV, and GV sequences, and no cross-reactivity was observed against other enteric viruses, including norovirus (NoV), rotavirus, astrovirus, and adenovirus [1].
• In a prospective work, we have studied the non-polio enterovirus (NPEV) excretion in spot urine and stools by four appropriate cell cultures, in four different groups: 20 exposed controls (GI), 88 patients with renal biopsy 'proven GN' (GII), 38 cases with 'proven nonGN' (GIII), and 9 with 'probable nonGN' (GIV) [2].

High impact information on KIAA1212

• Sequence analysis of the T-20 resistant domain (a.a. 547-549, GIV) revealed that 99% of the specimens (149 of 150) carried a T-20 sensitive genotype [3].
• While no mutations were found within a highly conserved 3-amino-acid sequence (GIV) known to be critical for fusion at baseline, after 14 days of therapy, virus from one patient in the 30-mg dose group (30-1) developed a mutation in this motif, specifically an aspartic acid (D) substitution for glycine (G) at position 36 [4].
• The alignment of the SaV full-length ORF1 amino acid sequences indicated that the dipeptides used for the cleavage sites were either E or Q at the P1 position and A, G or S at the P1' position, which were conserved in the GI, GII, GIII, GIV and GV SaV ORF1 polyprotein [5].
• Ultrastructural studies reveal that expression of the C-terminal HkRP1 domain causes an accumulation of internal membranes with an electron-dense coat [6].
• We propose that HkRP1 is involved in the process of tubulation of sorting nexin-1 positive membranes from early endosome subdomains [6].

Biological context of KIAA1212

• The reactivity was confirmed with SaV GI, GII, GIV, and GV control plasmids, and the efficiency ranged from 2.5 x 10(7) to 2.5 x 10(1) copies per tube [1].
• Among the 184 strains studied, no amino acid mutation was found in the highly conserved three amino acid motif at codons 36-38 (GIV) that are important determinants of viral susceptibility to enfuvirtide [7].
• GIII and IV exhibited statistically significant lower percentages of cell viability: GIV only at the 0 h experimental time, whereas in GIII this viability markedly diminished reaching values of 10% by 12 h [8].

Anatomical context of KIAA1212

• Girdin (GIRDers of actIN filament, also reported as APE, GIV, or HkRP1) is a novel protein expressed ubiquitously in mammals and was recently identified as a binding partner of the serine/threonine kinase Akt [9].
• From January 1995 to July 1996, the authors used Mitek GIV titanium anchors to treat seven patients with acute rupture of the Achilles tendon (four men, three women; average age 52.42 years; range, 33-62 years) [10].

Associations of KIAA1212 with chemical compounds

• The patients of GII, GIIII and GIV when using MT presented amelioration of sex symptoms, mainly satisfaction and desire (p<0.01); however, GIII at T1 (1.3+/-0.3) presented similar problem score results as compared to GIII at T2 (1.5+/-0.6) [11].
• The experimental groups were GI (control) no sodium alendronate, and GII, GIII, and GIV with sodium alendronate at the concentrations of 10(-5), 10(-6), and 10(-7) M, respectively [12].
• RESULTS: Teicoplanin release in the calcium sulfate powder added groups (GIII and GIV) was higher than that of GII [13].
• Eighty-eight samples of metallic supported feldspathic porcelain were randomly divided into four groups according to their surface preparation as follows: the porcelain was maintained intact (GI), roughened with a diamond bur (GII), etched with 10% hydrofluoric acid (GIII), or sandblasted with aluminum oxide (GIV) [14].
• Groups GIII and GIV had final irrigation with EDTA-T and citric acid, respectively, plus an association of irrigating solution and Er:YAG laser [15].

Analytical, diagnostic and therapeutic context of KIAA1212

• Procedures were also categorized into four different groups: GI, total abdominal colectomies; GII, segmental resections; GIII, diverting procedures; GIV, others (abdominoperineal resection, Hartmann's creation or closure, anterior resection, and rectopexy) [16].
• A significant improvement in change of cough scores was found in end of intervention (2-3 months) in those receiving PPI with a standardised mean difference of -0.41 (95%CI -0.75, -0.07) using GIV analysis on cross over trials [17].
• No fibers were added to group I (GI, control group); acrylic stain (AS) was added to GII and GIII in concentrations of 0.5 and 1.5% w/w, respectively; acrylic fibers (AF) were added to groups GIV and GV in concentrations of 0.5 and 1.5% w/w, respectively [18].
• The methods used were GI, visual inspection; GII, tactile inspection (explorer probe); GIII, conventional radiographic exam; GIV, digital radiographic exam (Digora for Windows 1.51 and 1.51N, SoredexOrion Co.); GV, low-intensity laser for diagnosis (DIAGNOdent, KaVo, Germany); and GVI, histological inspection [19].

References